Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Viramune
Viramune 200 mg tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-088109 · Präparat HOS-083615
Nevirapine concentrations not
measured, no effect is expected.
INTEGRASE INHIBITORS
Elvitegravir/cobicistat Interaction has not been studied. Coadministration of Viramune
Cobicistat, a cytochrome P450 3A with elvitegravir in combination
inhibitor significantly inhibits with cobicistat is not recommended
hepatic enzymes, as well as other (see section 4.4).
metabolic pathways. Therefore
coadministration would likely
result in altered plasma levels of
cobicistat and Viramune.
Raltegravir No clinical data available. Due to Raltegravir and Viramune can be
400 mg BID the metabolic pathway of co-administered without dose
raltegravir no interaction is adjustments.
expected.
ANTIBIOTICS
Clarithromycin Clarithromycin AUC 0.69 Clarithromycin exposure was
500 mg BID (0.62-0.76) significantly decreased, 14-OH
Clarithromycin Cmin 0.44 metabolite exposure increased.
(0.30-0.64) Because the clarithromycin active
Clarithromycin Cmax 0.77 metabolite has reduced activity
(0.69-0.86) against Mycobacterium avium-
intracellulare complex overall
Metabolite 14-OH clarithromycin activity against the pathogen may
AUC 1.42 (1.16-1.73) be altered. Alternatives to
Metabolite 14-OH clarithromycin clarithromycin, such as
Cmin 0 (0.68-1.49) azithromycin should be considered.
Metabolite 14-OH clarithromycin Close monitoring for hepatic
Cmax 1.47 (1.21-1.80) abnormalities is recommended
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cobicistat (HOS-088111) azithromycin (HOS-088112) clarithromycin (HOS-084517) raltegravir (HOS-086187) elvitegravir (HOS-088110)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage cf7f3bf4c95b2388228c494f913a21a4dc6fc418bee30f18d985d5b4c96318ce · Zeichen 12414–14588 im Abschnitt
Wechselwirkungen · Viramune
Viramune 50 mg/5 mL oral suspension · Abschnitt 4.5 · PDF-Seite 36
HOS-088207 · Präparat HOS-083615
INTEGRASE INHIBITORS
Elvitegravir/ Interaction has not been studied. Coadministration of Viramune
cobicistat Cobicistat, a cytochrome P450 3A with elvitegravir in combination
inhibitor significantly inhibits with cobicistat is not recommended
hepatic enzymes, as well as other (see section 4.4).
metabolic pathways. Therefore
coadministration would likely
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cobicistat (HOS-088111) elvitegravir (HOS-088110)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 698cb299912203229f679d41a0b4734a0987bf0c50be5f0893fc5900b057e43c · Zeichen 12641–13117 im Abschnitt
Wechselwirkungen · Viramune
Viramune 50 mg/5 mL oral suspension · Abschnitt 4.5 · PDF-Seite 36–37
HOS-088208 · Präparat HOS-083615
36
result in altered plasma levels of
cobicistat and Viramune.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cobicistat (HOS-088111)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 2212d208c549f94af3f6a7751b638fe378108cbd17c7daef58b7b1ef8b0d7b24 · Zeichen 13164–13265 im Abschnitt
Wechselwirkungen · Viramune
Viramune 400 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 62
HOS-088300 · Präparat HOS-083615
INTEGRASE INHIBITORS
Elvitegravir/ Interaction has not been studied. Coadministration of Viramune
cobicistat Cobicistat, a cytochrome P450 3A with elvitegravir in combination
inhibitor significantly inhibits with cobicistat is not recommended
hepatic enzymes, as well as other (see section 4.4).
metabolic pathways. Therefore
coadministration would likely
result in altered plasma levels of
cobicistat and Viramune.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cobicistat (HOS-088111) elvitegravir (HOS-088110)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage cdf86c86a6301476f55769a713e883729187c660ecb3e9f65bce1dd56e6e27a6 · Zeichen 12801–13365 im Abschnitt
Wechselwirkungen · Viread
Viread 123 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–10
HOS-110492 · Präparat HOS-093385
9
Medicinal product by Effects on drug levels Recommendation concerning
therapeutic areas Mean percent change in AUC, co-administration with 245 mg
(dose in mg) Cmax, Cmin tenofovir disoproxil
Adefovir dipivoxil AUC: ↔ Tenofovir disoproxil should not be
Cmax: ↔ administered concurrently with
adefovir dipivoxil
(see section 4.4).
Hepatitis C virus antiviral agents
Ledipasvir/Sofosbuvir Ledipasvir: Increased plasma concentrations
(90 mg/400 mg q.d.) + AUC: ↑ 96% of tenofovir resulting from
Atazanavir/Ritonavir Cmax: ↑ 68% co-administration of tenofovir
(300 mg q.d./100 mg q.d.) + Cmin: ↑ 118% disoproxil, ledipasvir/sofosbuvir
Emtricitabine/Tenofovir disoproxil and atazanavir/ritonavir may
(200 mg/245 mg q.d.)1 Sofosbuvir: increase adverse reactions related
AUC: ↔ to tenofovir disoproxil, including
Cmax: ↔ renal disorders. The safety of
tenofovir disoproxil when used
GS-3310072: with ledipasvir/sofosbuvir and a
AUC: ↔ pharmacokinetic enhancer (e.g.
Cmax: ↔ ritonavir or cobicistat) has not
Cmin: ↑ 42% been established.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) adefovir dipivoxil (HOS-110478) atazanavir (HOS-086180) sofosbuvir (HOS-108928) ledipasvir (HOS-110493) cobicistat (HOS-088111) hepatitis C virus (HOS-108813) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 824f9677703ef0bd8736160366b3629ad69b12899569fa4edf1bdab9fd603c0c · Zeichen 7039–9028 im Abschnitt
Wechselwirkungen · Viread
Viread 123 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10–11
HOS-110500 · Präparat HOS-093385
10
Medicinal product by Effects on drug levels Recommendation concerning
therapeutic areas Mean percent change in AUC, co-administration with 245 mg
(dose in mg) Cmax, Cmin tenofovir disoproxil
Ledipasvir/Sofosbuvir Ledipasvir: Increased plasma concentrations
(90 mg/400 mg q.d.) + AUC: ↔ of tenofovir resulting from
Darunavir/Ritonavir Cmax: ↔ co-administration of tenofovir
(800 mg q.d./100 mg q.d.) + Cmin: ↔ disoproxil, ledipasvir/sofosbuvir
Emtricitabine/Tenofovir disoproxil and darunavir/ritonavir may
(200 mg/245 mg q.d.)1 Sofosbuvir: increase adverse reactions related
AUC: ↓ 27% to tenofovir disoproxil, including
Cmax: ↓ 37% renal disorders. The safety of
tenofovir disoproxil when used
GS-3310072: with ledipasvir/sofosbuvir and a
AUC: ↔ pharmacokinetic enhancer (e.g.
Cmax: ↔ ritonavir or cobicistat) has not
Cmin: ↔ been established.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) sofosbuvir (HOS-108928) ledipasvir (HOS-110493) cobicistat (HOS-088111) darunavir (HOS-086181) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 087a97d32c6196144fac42069c01c95f98b657dbaf4644b79b530f187480c3be · Zeichen 10060–11640 im Abschnitt
Wechselwirkungen · Viread
Viread 123 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13–14
HOS-110514 · Präparat HOS-093385
13
Medicinal product by Effects on drug levels Recommendation concerning
therapeutic areas Mean percent change in AUC, co-administration with 245 mg
(dose in mg) Cmax, Cmin tenofovir disoproxil
Sofosbuvir/Velpatasvir Sofosbuvir: Increased plasma concentrations
(400 mg/100 mg q.d.) + AUC: ↔ of tenofovir resulting from
Atazanavir/Ritonavir Cmax: ↔ co-administration of tenofovir
(300 mg q.d./100 mg q.d.) + disoproxil, sofosbuvir/velpatasvir
Emtricitabine/Tenofovir disoproxil GS-3310072: and atazanavir/ritonavir may
(200 mg/245 mg q.d.) AUC: ↔ increase adverse reactions related
Cmax: ↔ to tenofovir disoproxil, including
Cmin: ↑ 42% renal disorders. The safety of
tenofovir disoproxil when used
Velpatasvir: with sofosbuvir/velpatasvir and a
AUC: ↑ 142% pharmacokinetic enhancer (e.g.
Cmax: ↑ 55% ritonavir or cobicistat) has not
Cmin: ↑ 301% been established.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) atazanavir (HOS-086180) sofosbuvir (HOS-108928) cobicistat (HOS-088111) velpatasvir (HOS-108929) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage a352840ea53b0c7aa2c2c1477faa3502b999395202d25ef8a0192525e4dfa26d · Zeichen 18217–19800 im Abschnitt
Wechselwirkungen · Viread
Viread 123 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14–15
HOS-110518 · Präparat HOS-093385
14
Medicinal product by Effects on drug levels Recommendation concerning
therapeutic areas Mean percent change in AUC, co-administration with 245 mg
(dose in mg) Cmax, Cmin tenofovir disoproxil
Sofosbuvir/Velpatasvir Sofosbuvir: Increased plasma concentrations
(400 mg/100 mg q.d.) + AUC: ↓28% of tenofovir resulting from
Darunavir/Ritonavir Cmax: ↓ 38% co-administration of tenofovir
(800 mg q.d./100 mg q.d.) + disoproxil, sofosbuvir/velpatasvir
Emtricitabine/Tenofovir disoproxil GS-3310072: and darunavir/ritonavir may
(200 mg/245 mg q.d.) AUC: ↔ increase adverse reactions related
Cmax: ↔ to tenofovir disoproxil, including
Cmin: ↔ renal disorders. The safety of
tenofovir disoproxil when used
Velpatasvir: with sofosbuvir/velpatasvir and a
AUC: ↔ pharmacokinetic enhancer (e.g.
Cmax: ↓ 24% ritonavir or cobicistat) has not
Cmin: ↔ been established.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) sofosbuvir (HOS-108928) cobicistat (HOS-088111) velpatasvir (HOS-108929) darunavir (HOS-086181) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 737e46afeb9439dde410899a01dd79d8a2f0e067b384f6b1c089de70a2e4dede · Zeichen 20772–22354 im Abschnitt
Wechselwirkungen · Viread
Viread 123 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 15–16
HOS-110522 · Präparat HOS-093385
15
Medicinal product by Effects on drug levels Recommendation concerning
therapeutic areas Mean percent change in AUC, co-administration with 245 mg
(dose in mg) Cmax, Cmin tenofovir disoproxil
Sofosbuvir/Velpatasvir Sofosbuvir: Increased plasma concentrations
(400 mg/100 mg q.d.) + AUC: ↓ 29% of tenofovir resulting from
Lopinavir/Ritonavir Cmax: ↓ 41% co-administration of tenofovir
(800 mg/200 mg q.d.) + disoproxil, sofosbuvir/velpatasvir
Emtricitabine/Tenofovir disoproxil GS-3310072: and lopinavir/ritonavir may
(200 mg/245 mg q.d.) AUC: ↔ increase adverse reactions related
Cmax: ↔ to tenofovir disoproxil, including
Cmin: ↔ renal disorders. The safety of
tenofovir disoproxil when used
Velpatasvir: with sofosbuvir/velpatasvir and a
AUC: ↔ pharmacokinetic enhancer (e.g.
Cmax: ↓ 30% ritonavir or cobicistat) has not
Cmin: ↑ 63% been established.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) lopinavir (HOS-086269) sofosbuvir (HOS-108928) cobicistat (HOS-088111) velpatasvir (HOS-108929) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 26c0232f6e9aca312defaa3abb7db0177d9af751e67aef58f622af58ce0b6a51 · Zeichen 23322–24904 im Abschnitt
Wechselwirkungen · Viread
Viread 123 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 18–19
HOS-110533 · Präparat HOS-093385
18
Medicinal product by Effects on drug levels Recommendation concerning
therapeutic areas Mean percent change in AUC, co-administration with 245 mg
(dose in mg) Cmax, Cmin tenofovir disoproxil
Sofosbuvir/Velpatasvir/ Sofosbuvir: Increased plasma concentrations
Voxilaprevir (400 mg/100 mg/ AUC: ↔ of tenofovir resulting from co-
100 mg+100 mg q.d.)3 + Darunavir Cmax: ↓ 30% administration of tenofovir
(800 mg q.d.) + Ritonavir (100 mg Cmin: N/A disoproxil,
q.d.) + Emtricitabine/Tenofovir sofosbuvir/velpatasvir/voxilaprevir
disoproxil (200 mg/245 mg q.d.) GS-3310072: and darunavir/ritonavir may
AUC: ↔ increase adverse reactions related
Cmax:↔ to tenofovir disoproxil, including
Cmin: N/A renal disorders.
The safety of tenofovir disoproxil
Velpatasvir: when used with
AUC: ↔ sofosbuvir/velpatasvir/voxilaprevir
Cmax: ↔ and a pharmacokinetic enhancer
Cmin: ↔ (e.g. ritonavir or cobicistat) has
not been established.
Voxilaprevir:
AUC: ↑ 143% The combination should be used
Cmax:↑ 72% with caution with frequent renal
Cmin: ↑ 300% monitoring (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) sofosbuvir (HOS-108928) cobicistat (HOS-088111) voxilaprevir (HOS-108930) velpatasvir (HOS-108929) darunavir (HOS-086181) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage d550c8d9097fb86a9733da7c544c1bce662495bf9924cb0e60e96c3044614d33 · Zeichen 31330–33402 im Abschnitt
Wechselwirkungen · Viread
Viread 163 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 49–50
HOS-110596 · Präparat HOS-093385
49
Medicinal product by Effects on drug levels Recommendation
therapeutic areas Mean percent change in AUC, Cmax, Cmin concerning
(dose in mg) co-administration with
245 mg tenofovir disoproxil
Hepatitis C virus antiviral agents
Ledipasvir/Sofosbuvir Ledipasvir: Increased plasma
(90 mg/400 mg q.d.) + AUC: ↑ 96% concentrations of tenofovir
Atazanavir/Ritonavir Cmax: ↑ 68% resulting from
(300 mg q.d./100 mg q.d.) + Cmin: ↑ 118% co-administration of tenofovir
Emtricitabine/Tenofovir disoproxil,
disoproxil Sofosbuvir: ledipasvir/sofosbuvir and
(200 mg/245 mg q.d.)1 AUC: ↔ atazanavir/ritonavir may
Cmax: ↔ increase adverse reactions
related to tenofovir disoproxil,
GS-3310072: including renal disorders. The
AUC: ↔ safety of tenofovir disoproxil
Cmax: ↔ when used with
Cmin: ↑ 42% ledipasvir/sofosbuvir and a
pharmacokinetic enhancer
Atazanavir: (e.g. ritonavir or cobicistat)
AUC: ↔ has not been established.
Cmax: ↔
Cmin: ↑ 63% The combination should be
used with caution with
Ritonavir: frequent renal monitoring, if
AUC: ↔ other alternatives are not
Cmax: ↔ available (see section 4.4).
Cmin: ↑ 45%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) atazanavir (HOS-086180) sofosbuvir (HOS-108928) ledipasvir (HOS-110493) cobicistat (HOS-088111) hepatitis C virus (HOS-108813) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 6c5102c58c0a5342683c6dffc2f5f0ed4e9e471a1d14b33916f9bf2e1e1b3bb9 · Zeichen 8813–11440 im Abschnitt
Wechselwirkungen · Viread
Viread 163 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 50–51
HOS-110599 · Präparat HOS-093385
50
Medicinal product by Effects on drug levels Recommendation
therapeutic areas Mean percent change in AUC, Cmax, Cmin concerning
(dose in mg) co-administration with
245 mg tenofovir disoproxil
Ledipasvir/Sofosbuvir Ledipasvir: Increased plasma
(90 mg/400 mg q.d.) + AUC: ↔ concentrations of tenofovir
Darunavir/Ritonavir Cmax: ↔ resulting from
(800 mg q.d./100 mg q.d.) + Cmin: ↔ co-administration of tenofovir
Emtricitabine/Tenofovir disoproxil,
disoproxil Sofosbuvir: ledipasvir/sofosbuvir and
(200 mg/245 mg q.d.)1 AUC: ↓ 27% darunavir/ritonavir may
Cmax: ↓ 37% increase adverse reactions
related to tenofovir disoproxil,
GS-3310072: including renal disorders. The
AUC: ↔ safety of tenofovir disoproxil
Cmax: ↔ when used with
Cmin: ↔ ledipasvir/sofosbuvir and a
pharmacokinetic enhancer
Darunavir: (e.g. ritonavir or cobicistat)
AUC: ↔ has not been established.
Cmax: ↔
Cmin: ↔ The combination should be
used with caution with
Ritonavir: frequent renal monitoring, if
AUC: ↔ other alternatives are not
Cmax: ↔ available (see section 4.4).
Cmin: ↑ 48%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) sofosbuvir (HOS-108928) ledipasvir (HOS-110493) cobicistat (HOS-088111) darunavir (HOS-086181) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage bdbba031567de86e144e97b81ef760d77dfbe989e81af41ca7d35743864c2e03 · Zeichen 11841–14333 im Abschnitt
Wechselwirkungen · Viread
Viread 163 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 53–54
HOS-110611 · Präparat HOS-093385
53
Medicinal product by Effects on drug levels Recommendation
therapeutic areas Mean percent change in AUC, Cmax, Cmin concerning
(dose in mg) co-administration with
245 mg tenofovir disoproxil
Sofosbuvir/Velpatasvir Sofosbuvir: Increased plasma
(400 mg/100 mg q.d.) + AUC: ↔ concentrations of tenofovir
Atazanavir/Ritonavir Cmax: ↔ resulting from
(300 mg q.d./100 mg q.d.) + co-administration of tenofovir
Emtricitabine/Tenofovir GS-3310072: disoproxil,
disoproxil AUC: ↔ sofosbuvir/velpatasvir and
(200 mg/245 mg q.d.) Cmax: ↔ atazanavir/ritonavir may
Cmin: ↑ 42% increase adverse reactions
related to tenofovir disoproxil,
Velpatasvir: including renal disorders. The
AUC: ↑ 142% safety of tenofovir disoproxil
Cmax: ↑ 55% when used with
Cmin: ↑ 301% sofosbuvir/velpatasvir and a
pharmacokinetic enhancer
Atazanavir: (e.g. ritonavir or cobicistat)
AUC: ↔ has not been established.
Cmax: ↔
Cmin: ↑ 39% The combination should be
used with caution with
Ritonavir: frequent renal monitoring (see
AUC: ↔ section 4.4).
Cmax: ↔
Cmin: ↑ 29%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) atazanavir (HOS-086180) sofosbuvir (HOS-108928) cobicistat (HOS-088111) velpatasvir (HOS-108929) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 97e1bc9f3b6c03c77c7d04d94f760c7fbda9ec9eabb9eb670e2965f8b6ad20d7 · Zeichen 20449–22870 im Abschnitt
Wechselwirkungen · Viread
Viread 163 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 54–55
HOS-110613 · Präparat HOS-093385
54
Medicinal product by Effects on drug levels Recommendation
therapeutic areas Mean percent change in AUC, Cmax, Cmin concerning
(dose in mg) co-administration with
245 mg tenofovir disoproxil
Sofosbuvir/Velpatasvir Sofosbuvir: Increased plasma
(400 mg/100 mg q.d.) + AUC: ↓28% concentrations of tenofovir
Darunavir/Ritonavir Cmax: ↓ 38% resulting from
(800 mg q.d./100 mg q.d.) + co-administration of tenofovir
Emtricitabine/Tenofovir GS-3310072: disoproxil,
disoproxil AUC: ↔ sofosbuvir/velpatasvir and
(200 mg/245 mg q.d.) Cmax: ↔ darunavir/ritonavir may
Cmin: ↔ increase adverse reactions
related to tenofovir disoproxil,
Velpatasvir: including renal disorders. The
AUC: ↔ safety of tenofovir disoproxil
Cmax: ↓ 24% when used with
Cmin: ↔ sofosbuvir/velpatasvir and a
pharmacokinetic enhancer
Darunavir: (e.g. ritonavir or cobicistat)
AUC: ↔ has not been established.
Cmax: ↔
Cmin: ↔ The combination should be
used with caution with
Ritonavir: frequent renal monitoring (see
AUC: ↔ section 4.4).
Cmax: ↔
Cmin: ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) sofosbuvir (HOS-108928) cobicistat (HOS-088111) velpatasvir (HOS-108929) darunavir (HOS-086181) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage e6335f4176b98a52989a9f36192d67ce8031012747a37072e892d128b679320b · Zeichen 23244–25660 im Abschnitt
Wechselwirkungen · Viread
Viread 163 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 55–56
HOS-110615 · Präparat HOS-093385
55
Medicinal product by Effects on drug levels Recommendation
therapeutic areas Mean percent change in AUC, Cmax, Cmin concerning
(dose in mg) co-administration with
245 mg tenofovir disoproxil
Sofosbuvir/Velpatasvir Sofosbuvir: Increased plasma
(400 mg/100 mg q.d.) + AUC: ↓ 29% concentrations of tenofovir
Lopinavir/Ritonavir Cmax: ↓ 41% resulting from
(800 mg/200 mg q.d.) + co-administration of tenofovir
Emtricitabine/Tenofovir GS-3310072: disoproxil,
disoproxil AUC: ↔ sofosbuvir/velpatasvir and
(200 mg/245 mg q.d.) Cmax: ↔ lopinavir/ritonavir may
Cmin: ↔ increase adverse reactions
related to tenofovir disoproxil,
Velpatasvir: including renal disorders. The
AUC: ↔ safety of tenofovir disoproxil
Cmax: ↓ 30% when used with
Cmin: ↑ 63% sofosbuvir/velpatasvir and a
pharmacokinetic enhancer
Lopinavir: (e.g. ritonavir or cobicistat)
AUC: ↔ has not been established.
Cmax: ↔
Cmin: ↔ The combination should be
used with caution with
Ritonavir: frequent renal monitoring (see
AUC: ↔ section 4.4).
Cmax: ↔
Cmin: ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) lopinavir (HOS-086269) sofosbuvir (HOS-108928) cobicistat (HOS-088111) velpatasvir (HOS-108929) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage f429fcd15aa6871cb839634b36d3ad1413e88ea18aacf119f35aa295ac448c15 · Zeichen 26038–28373 im Abschnitt
Wechselwirkungen · Viread
Viread 163 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 58–59
HOS-110627 · Präparat HOS-093385
58
Medicinal product by Effects on drug levels Recommendation
therapeutic areas Mean percent change in AUC, Cmax, Cmin concerning
(dose in mg) co-administration with
245 mg tenofovir disoproxil
Sofosbuvir/Velpatasvir/ Sofosbuvir: Increased plasma
Voxilaprevir (400 mg/100 mg/ AUC: ↔ concentrations of tenofovir
100 mg+100 mg q.d.)3 + Cmax: ↓ 30% resulting from co-
Darunavir (800 mg q.d.) + Cmin: N/A administration of tenofovir
Ritonavir (100 mg q.d.) + disoproxil,
Emtricitabine/Tenofovir GS-3310072: sofosbuvir/velpatasvir/voxilap
disoproxil (200 mg/245 mg q.d.) AUC: ↔ revir and darunavir/ritonavir
Cmax:↔ may increase adverse
Cmin: N/A reactions related to tenofovir
disoproxil, including renal
Velpatasvir: disorders.
AUC: ↔ The safety of tenofovir
Cmax: ↔ disoproxil when used with
Cmin: ↔ sofosbuvir/velpatasvir/voxilap
revir and a pharmacokinetic
Voxilaprevir: enhancer (e.g. ritonavir or
AUC: ↑ 143% cobicistat) has not been
Cmax:↑ 72% established.
Cmin: ↑ 300%
The combination should be
Darunavir: used with caution with
AUC: ↔ frequent renal monitoring (see
Cmax: ↔ section 4.4).
Cmin: ↓ 34%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) sofosbuvir (HOS-108928) cobicistat (HOS-088111) voxilaprevir (HOS-108930) velpatasvir (HOS-108929) darunavir (HOS-086181) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 8f90c3405a909c8e9cd0f1c3dec1c93cb05981de545d195f7ffe4f8d2624fc77 · Zeichen 34101–36770 im Abschnitt
Wechselwirkungen · Viread
Viread 204 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 89–90
HOS-110686 · Präparat HOS-093385
89
Medicinal product by Effects on drug levels Recommendation
therapeutic areas Mean percent change in AUC, Cmax, Cmin concerning
(dose in mg) co-administration with
245 mg tenofovir disoproxil
Hepatitis C virus antiviral agents
Ledipasvir/Sofosbuvir Ledipasvir: Increased plasma
(90 mg/400 mg q.d.) + AUC: ↑ 96% concentrations of tenofovir
Atazanavir/Ritonavir Cmax: ↑ 68% resulting from
(300 mg q.d./100 mg q.d.) + Cmin: ↑ 118% co-administration of tenofovir
Emtricitabine/Tenofovir disoproxil,
disoproxil Sofosbuvir: ledipasvir/sofosbuvir and
(200 mg/245 mg q.d.)1 AUC: ↔ atazanavir/ritonavir may
Cmax: ↔ increase adverse reactions
related to tenofovir disoproxil,
GS-3310072: including renal disorders. The
AUC: ↔ safety of tenofovir disoproxil
Cmax: ↔ when used with
Cmin: ↑ 42% ledipasvir/sofosbuvir and a
pharmacokinetic enhancer
Atazanavir: (e.g. ritonavir or cobicistat)
AUC: ↔ has not been established.
Cmax: ↔
Cmin: ↑ 63% The combination should be
used with caution with
Ritonavir: frequent renal monitoring, if
AUC: ↔ other alternatives are not
Cmax: ↔ available (see section 4.4).
Cmin: ↑ 45%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) atazanavir (HOS-086180) sofosbuvir (HOS-108928) ledipasvir (HOS-110493) cobicistat (HOS-088111) hepatitis C virus (HOS-108813) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage d322424ba6614c086cbb2bf3a6d9af968d8cf3f991cc6f4ee228b30a77ed726c · Zeichen 8813–11440 im Abschnitt
Wechselwirkungen · Viread
Viread 204 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 90–91
HOS-110689 · Präparat HOS-093385
90
Medicinal product by Effects on drug levels Recommendation
therapeutic areas Mean percent change in AUC, Cmax, Cmin concerning
(dose in mg) co-administration with
245 mg tenofovir disoproxil
Ledipasvir/Sofosbuvir Ledipasvir: Increased plasma
(90 mg/400 mg q.d.) + AUC: ↔ concentrations of tenofovir
Darunavir/Ritonavir Cmax: ↔ resulting from
(800 mg q.d./100 mg q.d.) + Cmin: ↔ co-administration of tenofovir
Emtricitabine/Tenofovir disoproxil,
disoproxil Sofosbuvir: ledipasvir/sofosbuvir and
(200 mg/245 mg q.d.)1 AUC: ↓ 27% darunavir/ritonavir may
Cmax: ↓ 37% increase adverse reactions
related to tenofovir disoproxil,
GS-3310072: including renal disorders. The
AUC: ↔ safety of tenofovir disoproxil
Cmax: ↔ when used with
Cmin: ↔ ledipasvir/sofosbuvir and a
pharmacokinetic enhancer
Darunavir: (e.g. ritonavir or cobicistat)
AUC: ↔ has not been established.
Cmax: ↔
Cmin: ↔ The combination should be
used with caution with
Ritonavir: frequent renal monitoring, if
AUC: ↔ other alternatives are not
Cmax: ↔ available (see section 4.4).
Cmin: ↑ 48%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) sofosbuvir (HOS-108928) ledipasvir (HOS-110493) cobicistat (HOS-088111) darunavir (HOS-086181) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage e284358b6ca38a0282224d92c8c26b67e60192ffc14ae6f0af344817caf4e595 · Zeichen 11841–14333 im Abschnitt
Wechselwirkungen · Viread
Viread 204 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 93–94
HOS-110701 · Präparat HOS-093385
93
Medicinal product by Effects on drug levels Recommendation
therapeutic areas Mean percent change in AUC, Cmax, Cmin concerning
(dose in mg) co-administration with
245 mg tenofovir disoproxil
Sofosbuvir/Velpatasvir Sofosbuvir: Increased plasma
(400 mg/100 mg q.d.) + AUC: ↔ concentrations of tenofovir
Atazanavir/Ritonavir Cmax: ↔ resulting from
(300 mg q.d./100 mg q.d.) + co-administration of tenofovir
Emtricitabine/Tenofovir GS-3310072: disoproxil,
disoproxil AUC: ↔ sofosbuvir/velpatasvir and
(200 mg/245 mg q.d.) Cmax: ↔ atazanavir/ritonavir may
Cmin: ↑ 42% increase adverse reactions
related to tenofovir disoproxil,
Velpatasvir: including renal disorders. The
AUC: ↑ 142% safety of tenofovir disoproxil
Cmax: ↑ 55% when used with
Cmin: ↑ 301% sofosbuvir/velpatasvir and a
pharmacokinetic enhancer
Atazanavir: (e.g. ritonavir or cobicistat)
AUC: ↔ has not been established.
Cmax: ↔
Cmin: ↑ 39% The combination should be
used with caution with
Ritonavir: frequent renal monitoring (see
AUC: ↔ section 4.4).
Cmax: ↔
Cmin: ↑ 29%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) atazanavir (HOS-086180) sofosbuvir (HOS-108928) cobicistat (HOS-088111) velpatasvir (HOS-108929) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage e29fa3d6609425d21d681c1e7f025d13a10a008a16dea37f754f5643e1e060c8 · Zeichen 20449–22870 im Abschnitt
Wechselwirkungen · Viread
Viread 204 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 94–95
HOS-110703 · Präparat HOS-093385
94
Medicinal product by Effects on drug levels Recommendation
therapeutic areas Mean percent change in AUC, Cmax, Cmin concerning
(dose in mg) co-administration with
245 mg tenofovir disoproxil
Sofosbuvir/Velpatasvir Sofosbuvir: Increased plasma
(400 mg/100 mg q.d.) + AUC: ↓28% concentrations of tenofovir
Darunavir/Ritonavir Cmax: ↓ 38% resulting from
(800 mg q.d./100 mg q.d.) + co-administration of tenofovir
Emtricitabine/Tenofovir GS-3310072: disoproxil,
disoproxil AUC: ↔ sofosbuvir/velpatasvir and
(200 mg/245 mg q.d.) Cmax: ↔ darunavir/ritonavir may
Cmin: ↔ increase adverse reactions
related to tenofovir disoproxil,
Velpatasvir: including renal disorders. The
AUC: ↔ safety of tenofovir disoproxil
Cmax: ↓ 24% when used with
Cmin: ↔ sofosbuvir/velpatasvir and a
pharmacokinetic enhancer
Darunavir: (e.g. ritonavir or cobicistat)
AUC: ↔ has not been established.
Cmax: ↔
Cmin: ↔ The combination should be
used with caution with
Ritonavir: frequent renal monitoring (see
AUC: ↔ section 4.4).
Cmax: ↔
Cmin: ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) sofosbuvir (HOS-108928) cobicistat (HOS-088111) velpatasvir (HOS-108929) darunavir (HOS-086181) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 44481f5a7aa3f713b8da7f6a789ab70c5b5e13f18cb6b4519cc7c72f41e756c6 · Zeichen 23244–25660 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.